Nikhil Pandey - Academia.edu (original) (raw)

Papers by Nikhil Pandey

Research paper thumbnail of Evaluation of knowledge resources for public health reporting logic: Implications for knowledge authoring and management

Online journal of public health informatics, 2011

To control disease, laboratories and providers are required to report conditions to public health... more To control disease, laboratories and providers are required to report conditions to public health authorities. Reporting logic is defined in a variety of resources, but there is no single resource available for reporters to access the list of reportable events and computable reporting logic for any jurisdiction. In order to develop evidence-based requirements for authoring such knowledge, we evaluated reporting logic in the Council of State and Territorial Epidemiologist (CSTE) position statements to assess its readiness for automated systems and identify features that should be considered when designing an authoring interface; we evaluated codes in the Reportable Condition Mapping Tables (RCMT) relative to the nationally-defined reporting logic, and described the high level business processes and knowledge required to support laboratory-based public health reporting. We focused on logic for viral hepatitis. We found that CSTE tabular logic was unnecessarily complex (sufficient cond...

Research paper thumbnail of Biodegradable Thermal-Responsive Dual-Imaging Enabled Nanoparticles

Zhiwei Xie1, Parth Jadeja2, Jyothi U. Menon2, Dheeraj Thakore2, Nikhil Pandey2, Jian Yang1*, Kyta... more Zhiwei Xie1, Parth Jadeja2, Jyothi U. Menon2, Dheeraj Thakore2, Nikhil Pandey2, Jian Yang1*, Kytai T. Nguyen2* 1 Department of Biomedical Engineering, Materials Research Institute, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, 16802. * Email: jxy30@psu.edu 2 Department of Bioengineering, The University of Texas at Arlington, Arlington, TX. * Email: knguyen@uta.edu Statement of Purpose: Current cancer management is dedicated in developing new techniques for earlier diagnosis and controlled drug delivery. Common diagnostic modalities such as magnetic resonance imaging (MRI), positron emission tomography, and optical imaging all individually have different limitations such as low sensitivity, low spatial resolution, toxicity of contrast agents, and inaccurate diagnosis. Dual-/multi-modal imaging systems may overcome these limitations by taking advantages of various individual techniques. For instance, MRI provides exceptional tissue contrast, pen...

Fig. 1 Images of water, BPLP, BPLP-PVCL41 and BPLP-PVCL45 solutions under (a) 25°C, (b) 45°C, and (c) UV light. (d) and (e) are MR phantom images of BPLP-PVCL41 and BPLP-PVCL45 with Gd loaded. ili, iv, V are nanoparticle concentrations of 0.5, 1, and 2 mg/ml. i and ii are controls without Gd. Conclusions: | We _— synthesized __ biodegradable fluorescent thermo-responsive nanoparticles by copolymerizing BPLP and PVCL. These cytocompatible degradable nanoparticles showed dual- imaging modalities to label cancer cells as well as temperature-triggered drug release profiles. BPLP- PVCL nanoparticles are promising candidates for theranostic drug delivery.

Research paper thumbnail of Characterization of Photoluminescent Polylactone-Based Nanoparticles for Their Applications in Cardiovascular Diseases

Frontiers in Bioengineering and Biotechnology

Cardiovascular diseases (CVD) affect a large number of the population across the globe and are th... more Cardiovascular diseases (CVD) affect a large number of the population across the globe and are the leading cause of death worldwide. Nanotechnology-based drug delivery has currently offered novel therapeutic options to treat these diseases, yet combination of both diagnostic and therapeutic abilities is further needed to understand factors and/or mechanisms that affect the treatment in order to design better therapies to challenge CVD. Biodegradable photoluminescent polylactones (BPLPLs) enable to bridge this gap as these materials exhibit a stable, long-term intrinsic fluorescence as well as offers excellent cytocompatibility and biodegradability properties. Herein, we formulated three different BPLPL based nanoparticles (NPs), including BPLP-co-poly (L-lactic acid) (BPLPL-PLLA), BPLP-co-poly (lactic-co-glycolic acid) copolymers with lactic acid and glycolic acid ratios of 75:25 (BPLPL-PLGA75:25) and 50:50 (BPLPL-PLGA50:50), and extensively evaluated their suitability as theranostic nanocarriers for CVD applications. All BPLPL based NPs were <160 nm in size and had photoluminescence characteristics and tunable release kinetics of encapsulated protein model depending on polylactones copolymerized with BPLP materials. Compared to BPLPL-PLLA NPs, BPLPL-PLGA NPs demonstrated excellent stability in various formulations including deionized water, serum, saline, and simulated body fluid over 2 days. In vitro cell studies with human umbilical vein derived endothelial cells showed dose-dependent accumulation of BPLPL-based NPs, and BPLPL-PLGA NPs presented superior compatibility with endothelial cells in terms of viability with minimal effects on cellular functions such as nitric oxide production. Furthermore, all BPLPL NPs displayed hemocompatibility with no effect on whole blood kinetic profiles, were non-hemolytic, and consisted of comparable platelet responses such as platelet adhesion and activation to those of PLGA, an FDA approved material. Overall, our results demonstrated that BPLPL-PLGA based NPs have better physical and biological properties than BPLPL-PLLA; hence they have potential to be utilized as functional nanocarriers for therapy and diagnosis of CVD.

Research paper thumbnail of Evaluation of knowledge resources for public health reporting logic: Implications for knowledge authoring and management

Online journal of public health informatics, 2011

To control disease, laboratories and providers are required to report conditions to public health... more To control disease, laboratories and providers are required to report conditions to public health authorities. Reporting logic is defined in a variety of resources, but there is no single resource available for reporters to access the list of reportable events and computable reporting logic for any jurisdiction. In order to develop evidence-based requirements for authoring such knowledge, we evaluated reporting logic in the Council of State and Territorial Epidemiologist (CSTE) position statements to assess its readiness for automated systems and identify features that should be considered when designing an authoring interface; we evaluated codes in the Reportable Condition Mapping Tables (RCMT) relative to the nationally-defined reporting logic, and described the high level business processes and knowledge required to support laboratory-based public health reporting. We focused on logic for viral hepatitis. We found that CSTE tabular logic was unnecessarily complex (sufficient cond...

Research paper thumbnail of Biodegradable Thermal-Responsive Dual-Imaging Enabled Nanoparticles

Zhiwei Xie1, Parth Jadeja2, Jyothi U. Menon2, Dheeraj Thakore2, Nikhil Pandey2, Jian Yang1*, Kyta... more Zhiwei Xie1, Parth Jadeja2, Jyothi U. Menon2, Dheeraj Thakore2, Nikhil Pandey2, Jian Yang1*, Kytai T. Nguyen2* 1 Department of Biomedical Engineering, Materials Research Institute, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, 16802. * Email: jxy30@psu.edu 2 Department of Bioengineering, The University of Texas at Arlington, Arlington, TX. * Email: knguyen@uta.edu Statement of Purpose: Current cancer management is dedicated in developing new techniques for earlier diagnosis and controlled drug delivery. Common diagnostic modalities such as magnetic resonance imaging (MRI), positron emission tomography, and optical imaging all individually have different limitations such as low sensitivity, low spatial resolution, toxicity of contrast agents, and inaccurate diagnosis. Dual-/multi-modal imaging systems may overcome these limitations by taking advantages of various individual techniques. For instance, MRI provides exceptional tissue contrast, pen...

Fig. 1 Images of water, BPLP, BPLP-PVCL41 and BPLP-PVCL45 solutions under (a) 25°C, (b) 45°C, and (c) UV light. (d) and (e) are MR phantom images of BPLP-PVCL41 and BPLP-PVCL45 with Gd loaded. ili, iv, V are nanoparticle concentrations of 0.5, 1, and 2 mg/ml. i and ii are controls without Gd. Conclusions: | We _— synthesized __ biodegradable fluorescent thermo-responsive nanoparticles by copolymerizing BPLP and PVCL. These cytocompatible degradable nanoparticles showed dual- imaging modalities to label cancer cells as well as temperature-triggered drug release profiles. BPLP- PVCL nanoparticles are promising candidates for theranostic drug delivery.

Research paper thumbnail of Characterization of Photoluminescent Polylactone-Based Nanoparticles for Their Applications in Cardiovascular Diseases

Frontiers in Bioengineering and Biotechnology

Cardiovascular diseases (CVD) affect a large number of the population across the globe and are th... more Cardiovascular diseases (CVD) affect a large number of the population across the globe and are the leading cause of death worldwide. Nanotechnology-based drug delivery has currently offered novel therapeutic options to treat these diseases, yet combination of both diagnostic and therapeutic abilities is further needed to understand factors and/or mechanisms that affect the treatment in order to design better therapies to challenge CVD. Biodegradable photoluminescent polylactones (BPLPLs) enable to bridge this gap as these materials exhibit a stable, long-term intrinsic fluorescence as well as offers excellent cytocompatibility and biodegradability properties. Herein, we formulated three different BPLPL based nanoparticles (NPs), including BPLP-co-poly (L-lactic acid) (BPLPL-PLLA), BPLP-co-poly (lactic-co-glycolic acid) copolymers with lactic acid and glycolic acid ratios of 75:25 (BPLPL-PLGA75:25) and 50:50 (BPLPL-PLGA50:50), and extensively evaluated their suitability as theranostic nanocarriers for CVD applications. All BPLPL based NPs were <160 nm in size and had photoluminescence characteristics and tunable release kinetics of encapsulated protein model depending on polylactones copolymerized with BPLP materials. Compared to BPLPL-PLLA NPs, BPLPL-PLGA NPs demonstrated excellent stability in various formulations including deionized water, serum, saline, and simulated body fluid over 2 days. In vitro cell studies with human umbilical vein derived endothelial cells showed dose-dependent accumulation of BPLPL-based NPs, and BPLPL-PLGA NPs presented superior compatibility with endothelial cells in terms of viability with minimal effects on cellular functions such as nitric oxide production. Furthermore, all BPLPL NPs displayed hemocompatibility with no effect on whole blood kinetic profiles, were non-hemolytic, and consisted of comparable platelet responses such as platelet adhesion and activation to those of PLGA, an FDA approved material. Overall, our results demonstrated that BPLPL-PLGA based NPs have better physical and biological properties than BPLPL-PLLA; hence they have potential to be utilized as functional nanocarriers for therapy and diagnosis of CVD.